Evidence map›Paper›PMID 30445646›Full record

ArticleNeurosurgery2019

Presence of Histopathological Treatment Effects at Resection of Recurrent Glioblastoma: Incidence and Effect on Outcome.

Cecilia L Dalle Ore, Ankush Chandra, Jonathan Rick, Darryl Lau, Maryam Shahin, Alan T Nguyen, Michael McDermott, Mitchel S Berger, Manish K Aghi

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Neurosurgery, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Cecilia L Dalle OreDepartment of Neurological Surgery, University of California, San Francisco, San Francisco, California.
Ankush ChandraDepartment of Neurological Surgery, University of California, San Francisco, San Francisco, California.
Jonathan RickDepartment of Neurological Surgery, University of California, San Francisco, San Francisco, California.
Darryl LauDepartment of Neurological Surgery, University of California, San Francisco, San Francisco, California.
Maryam ShahinDepartment of Neurological Surgery, University of California, San Francisco, San Francisco, California.
Alan T NguyenDepartment of Neurological Surgery, University of California, San Francisco, San Francisco, California.
Michael McDermottDepartment of Neurological Surgery, University of California, San Francisco, San Francisco, California.
Mitchel S BergerDepartment of Neurological Surgery, University of California, San Francisco, San Francisco, California.
Manish K AghiDepartment of Neurological Surgery, University of California, San Francisco, San Francisco, California.

Funding

Tumor cell and microenvironment changes causing antiangiogenic therapy resistanceR01NS079697 · NINDS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI AGHI, MANISH · 2013 to 2021
$3.2M
Modeling and druggable-genome screening of glioblastoma invasion using regional biopsy-guided biomaterials systemsR01CA227136 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI AGHI, MANISH · 2018 to 2022
$2.2M
NCI NIH HHS R01 CA227136NINDS NIH HHS R01 NS079697
6 · The paper itself

Abstract

backgroundResection may be appropriate for select patients with recurrent glioblastoma. The incidence of histopathological findings related to prior treatment and their prognostic implications are incompletely characterized.

objectiveTo quantify the incidence and survival outcomes associated with treatment effect at resection of recurrent glioblastoma (GBM).

methodsPatients who underwent resection for recurrent GBM were retrospectively reviewed, and pathology, treatment history, and survival data were collected. Treatment effect was defined as any component of treatment-related changes on pathology.

resultsIn total, 110 patients underwent 146 reoperations. Median age at first reoperation was 57.2 yr and overall survival from reoperation was 10.8 mo. Treatment effect of any kind was noted in 81 of 146 reoperations (55%). Increased treatment effect was observed closer to radiotherapy; by quartile of time from radiotherapy, the rates of treatment effect were 77.8%, 55.6%, 40.7%, and 44.4% (P = .028). Treatment effect was associated with earlier reoperation (8.9 vs 13.8 mo after radiotherapy, P = .003), and the presence of treatment effect did not impact survival from primary surgery (25.4 vs 24.3 mo, P = .084). Patients treated with bevacizumab prior to reoperation were less likely to have treatment effect (20% vs 65%, P < .001).

conclusionHistopathological treatment-related changes are evident in a majority of patients undergoing resection for recurrent glioblastoma. There was no association of treatment effect with overall survival from primary surgery.

Indexed as

AdultAgedBrain NeoplasmsFemaleGlioblastomaHumansIncidenceMaleMiddle AgedNeoplasm Recurrence, LocalReoperationRetrospective StudiesTreatment OutcomeYoung AdultBevacizumabGlioblastomaRadiation necrosisRecurrentTreatment effect

Identifiers

PMID30445646
PMCPMC7054709

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.